717 related articles for article (PubMed ID: 26430314)
1. Dual time point fluorodeoxyglucose positron emission tomography/computed tomography in differentiation between malignant and benign lesions in cancer patients. Does it always work?
Saleh Farghaly HR; Mohamed Sayed MH; Nasr HA; Abdelaziz Maklad AM
Indian J Nucl Med; 2015; 30(4):314-9. PubMed ID: 26430314
[TBL] [Abstract][Full Text] [Related]
2. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
3. Dual-time point
Parghane RV; Basu S
Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277
[TBL] [Abstract][Full Text] [Related]
4. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue.
Krishnaraju VS; Kumar R; Mittal BR; Sharma V; Singh H; Nada R; Bal A; Rohilla M; Singh H; Rana SS
Eur Radiol; 2021 Apr; 31(4):2199-2208. PubMed ID: 33001304
[TBL] [Abstract][Full Text] [Related]
7. Dual time point [18F]Flurodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computed Tomography (CT) with water gastric distension in differentiation between malignant and benign gastric lesions.
Farghaly H; Alshareef M; Alqarni A; Sayed M; Nasr H
Eur J Radiol Open; 2020; 7():100268. PubMed ID: 32964074
[TBL] [Abstract][Full Text] [Related]
8. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions.
Tian R; Su M; Tian Y; Li F; Li L; Kuang A; Zeng J
Skeletal Radiol; 2009 May; 38(5):451-8. PubMed ID: 19205695
[TBL] [Abstract][Full Text] [Related]
9. (18)F-FDG and (18)F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes.
Rayamajhi SJ; Mittal BR; Maturu VN; Agarwal R; Bal A; Dey P; Shukla J; Gupta D
Ann Nucl Med; 2016 Apr; 30(3):207-16. PubMed ID: 26661845
[TBL] [Abstract][Full Text] [Related]
10. Preliminary clinical assessment of dynamic
Shinya T; Otomi Y; Kubo M; Kinoshita M; Takechi K; Uyama N; Yamanaka M; Terazawa K; Toba H; Bando Y; Otsuka H; Harada M
Ann Nucl Med; 2019 Jun; 33(6):414-423. PubMed ID: 30911883
[TBL] [Abstract][Full Text] [Related]
11. Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma.
Shinya T; Fujii S; Asakura S; Taniguchi T; Yoshio K; Alafate A; Sato S; Yoshino T; Kanazawa S
Ann Nucl Med; 2012 Oct; 26(8):616-21. PubMed ID: 22692457
[TBL] [Abstract][Full Text] [Related]
12. Characterization of pulmonary lesions with low F-18 FDG uptake using double phase F-18 FDG PET/CT: comparison of visual and quantitative analyses.
Kim IJ; Kim SJ; Kim YS; Lee TH; Jeong YJ
Neoplasma; 2009; 56(1):33-9. PubMed ID: 19152243
[TBL] [Abstract][Full Text] [Related]
13. Dual-time-point [18F]-FDG PET/CT in the diagnostic evaluation of suspicious breast lesions.
Caprio MG; Cangiano A; Imbriaco M; Soscia F; Di Martino G; Farina A; Avitabile G; Pace L; Forestieri P; Salvatore M
Radiol Med; 2010 Mar; 115(2):215-24. PubMed ID: 20017002
[TBL] [Abstract][Full Text] [Related]
14. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of FDG-PET/CT for Detection of Incidental Pre-Malignant and Malignant Colonic Lesions - Correlation with Colonoscopic and Histopathologic Findings.
Kunawudhi A; Wong AK; Alkasab TK; Mahmood U
Asian Pac J Cancer Prev; 2016; 17(8):4143-7. PubMed ID: 27644675
[TBL] [Abstract][Full Text] [Related]
16. Differentiation between malignancy and inflammation in pulmonary ground-glass nodules: The feasibility of integrated (18)F-FDG PET/CT.
Chun EJ; Lee HJ; Kang WJ; Kim KG; Goo JM; Park CM; Lee CH
Lung Cancer; 2009 Aug; 65(2):180-6. PubMed ID: 19155090
[TBL] [Abstract][Full Text] [Related]
17. Role of delayed-time-point imaging during abdominal and pelvic cancer screening using FDG-PET/CT in the general population.
Naganawa S; Yoshikawa T; Yasaka K; Maeda E; Hayashi N; Abe O
Medicine (Baltimore); 2017 Nov; 96(46):e8832. PubMed ID: 29145346
[TBL] [Abstract][Full Text] [Related]
18. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization.
Choi JY; Lee KS; Kim HJ; Shim YM; Kwon OJ; Park K; Baek CH; Chung JH; Lee KH; Kim BT
J Nucl Med; 2006 Apr; 47(4):609-15. PubMed ID: 16595494
[TBL] [Abstract][Full Text] [Related]
19. Dual-phase F-18 FDG PET-CT in staging and lymphoscintigraphy for detection of sentinel lymph nodes in oral cavity cancers.
Sürücü E; Polack BD; Demir Y; Durmuşoğlu M; Ekmekçi S; Sarıoğlu S; Çelik AO; Ada E; İkiz AÖ
Clin Imaging; 2015; 39(5):781-6. PubMed ID: 25721710
[TBL] [Abstract][Full Text] [Related]
20. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.
Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
Ann Nucl Med; 2009 Aug; 23(6):523-31. PubMed ID: 19444550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]